Question 1

What is CardiAction?

Accepted Answer

CardiAction is a cardiovascular health assessment platform that helps people understand their heart and artery health through non-invasive screening (no blood tests needed). Unlike a typical blood pressure check, CardiAction measures central blood pressure and arterial function, which research has shown to be stronger predictors of cardiovascular events such as heart attack and stroke.

CardiAction offers two products:

CardiAction PreScreen is an online cardiovascular risk assessment. It takes 2 to 5 minutes, requires no blood test or special equipment, and can be completed on any internet-connected smartphone, tablet or computer. PreScreen uses key biometrics to estimate your cardiovascular risk and provides an immediate result.

CardiAction ProScreen is an in-person cardiovascular health screening delivered through pharmacy and clinic networks in Australia and New Zealand. ProScreen uses the Uscom BP+, a TGA-registered and FDA-cleared pulse wave analysis (PWA) device, to directly measure central blood pressure and arterial health with clinical-grade accuracy. Your results are processed through the CardiAction ProScreen platform, which generates a detailed personalised report of the key findings including your individual readings, and a tailored action plan to help reduce your risk immediately.

Question 2

What biometrics does CardiAction use?

Accepted Answer

CardiAction PreScreen uses key biometric indicators that are scientifically linked to cardiovascular risk, including blood pressure, resting heart rate, height, waist circumference and gender.

CardiAction ProScreen measures all of the above plus a comprehensive set of central haemodynamic metrics through pulse wave analysis, including central systolic blood pressure (cSBP), augmentation pressure (AP), central pulse pressure (cPP), augmentation index (AIx), ejection duration (ED) and subendocardial viability ratio (SEVR). Each metric is assessed against the CardiAction Target Range, which is calibrated to support early identification of cardiovascular risk before symptoms emerge.

Question 3

How accurate is CardiAction?

Accepted Answer

CardiAction PreScreen estimates central systolic blood pressure with approximately 80% accuracy based on self-reported biometrics. It has been independently validated by Griffith University in Australia.

CardiAction ProScreen directly measures central blood pressure using the Uscom BP+ pulse wave analysis device. The BP+ has been validated against invasive catheter measurements and is the first non-invasive central blood pressure monitor to meet ARTERY Society Gold Standard validation with micromanometer catheters. This provides a level of measurement detail and clinical insight that is not available from a standard blood pressure check.

Question 4

What is the PreScreen CardiAction Risk Indicator?

Accepted Answer

Your CardiAction Risk Indicator from PreScreen is a personalised classification based on your results. It reflects your overall cardiovascular risk profile and guides recommended next steps. There are three levels:

Low - Your results indicate your cardiovascular system is functioning well. Continue maintaining healthy habits.

Medium - Consider taking action and seeking out a CardiAction ProScreen in-clinic service to more accurately assess your risks.

High - Attention needed. You have completed your CardiAction risk assessment and your results suggest your cardiovascular health needs immediate focus. Because you are in the High Risk category, it is essential that you see a health professional to understand your risks and take the right steps. A CardiAction ProScreen in-clinic screening will give you a far more detailed and accurate picture of your heart and artery health.

Question 5

Is CardiAction a medical device?

Accepted Answer

CardiAction is a health screening platform, not a diagnostic device. It provides an indicative cardiovascular risk assessment based on biometric data and is designed to help people decide whether to seek further medical evaluation.

The Uscom BP+ device used in ProScreen in-clinic screenings is a TGA-registered (ARTG ID 227735) and FDA 510(k)-cleared medical device for pulse wave analysis and central blood pressure measurement.

Question 6

Can CardiAction replace a doctor's assessment?

Accepted Answer

No. CardiAction does not replace your GP or existing screening pathways. It enhances them. CardiAction is an adjunct, not an alternative, to guideline-based cardiovascular prevention. It is a measurement and engagement service that helps people take the right next step earlier, typically GP follow-up and evidence-based care. Anyone with elevated results should consult a healthcare provider for further assessment.

Question 7

What happens after a ProScreen in-clinic screening?

Accepted Answer

After your in-clinic screening you will receive a personalised report by email containing your individual results, an explanation of what each measurement means, and a tailored action plan with recommendations covering nutrition, physical activity, sleep and stress management. Your screener will also walk you through your results at the time of your appointment.

If your results suggest elevated cardiovascular risk, you will be encouraged to share your report with your GP for further evaluation.

Question 8

Who delivers ProScreen screenings?

Accepted Answer

ProScreen screenings are delivered by trained screeners operating under approved protocols. Screeners are not doctors or registered health practitioners and will not provide a diagnosis or medical advice. The CardiAction platform and screening protocols are developed under the guidance of registered medical practitioners.

Question 9

How can pharmacies use CardiAction?

Accepted Answer

Pharmacies can offer CardiAction ProScreen as an in-store cardiovascular health screening service. Screenings are delivered through a scheduled clinic model and can be integrated into existing pharmacy health services, medication management programs, or preventive health initiatives. The ProScreen platform handles appointment booking, screening workflows, clinical reporting and patient follow-up.

Question 10

How can health screening organisations use CardiAction?

Accepted Answer

Health screening providers can sub-license the CardiAction ProScreen platform to deliver cardiovascular risk assessments at scale. ProScreen provides a cloud-based, multi-tenant platform that supports multiple locations, screener management, clinical reporting, and integration with scheduling and payroll systems.

Question 11

How can government health agencies use CardiAction?

Accepted Answer

Governments and public health agencies can deploy CardiAction to support large-scale preventive health initiatives. CardiAction PreScreen enables mass population screening without the need for clinical infrastructure, while ProScreen provides clinical-grade in-person assessments that can be targeted at higher-risk or underserved populations, including rural and indigenous communities.

Question 12

Is CardiAction available internationally?

Accepted Answer

CardiAction is currently operational in Australia and New Zealand, with the platform designed for global deployment. The platform maintains HIPAA-aligned security controls and can be adapted to meet local regulatory and population health requirements.

Question 13

How secure is my data?

Accepted Answer

CardiAction follows strict data security and privacy protocols. In Australia, the platform complies with the Australian Privacy Act 1988 and the Australian Privacy Principles. In New Zealand, it complies with the Privacy Act 2020. The platform is designed to HIPAA-aligned standards to support future international deployment. All screening data is stored securely and handled in accordance with applicable privacy laws.

Question 14

Does CardiAction use AI?

Accepted Answer

CardiAction is developing AI-enabled features for ProScreen. Future releases will include AI-assisted clinical interpretation that generates deeper personalised insights from screening data. No personally identifiable health information will be shared with AI models. Only de-identified metrics and anonymised context will be used, ensuring your privacy is protected while delivering meaningful, personalised guidance.

Question 15

Is CardiAction suitable for workplace health programs?

Accepted Answer

Yes. CardiAction PreScreen can be deployed as part of corporate wellness initiatives to provide employees with an accessible cardiovascular risk assessment. For organisations seeking more detailed insights, CardiAction ProScreen can be offered through on-site or pharmacy-based screening events.

Question 16

Is CardiAction continuously improving?

Accepted Answer

Yes. CardiAction is backed by ongoing research and development. The platform is continually refined to enhance accuracy, expand its clinical evidence base, and improve the personalisation of results and action plans.

Question 17

How do I get started?

Accepted Answer

To take an online cardiovascular risk assessment, visit cardiaction.com/prescreen.

To book an in-person ProScreen screening at a pharmacy near you, visit cardiactionscreening.com.au (Australia) or healthscreeningnz.com (New Zealand).

For partnership, licensing or government enquiries, contact info@cardiaction.com.

Frequently Asked Questions

Get Started with CardiAction Today